Correlation Between NextCure and Achilles Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both NextCure and Achilles Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NextCure and Achilles Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NextCure and Achilles Therapeutics PLC, you can compare the effects of market volatilities on NextCure and Achilles Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NextCure with a short position of Achilles Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NextCure and Achilles Therapeutics.

Diversification Opportunities for NextCure and Achilles Therapeutics

-0.59
  Correlation Coefficient

Excellent diversification

The 3 months correlation between NextCure and Achilles is -0.59. Overlapping area represents the amount of risk that can be diversified away by holding NextCure and Achilles Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Achilles Therapeutics PLC and NextCure is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NextCure are associated (or correlated) with Achilles Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Achilles Therapeutics PLC has no effect on the direction of NextCure i.e., NextCure and Achilles Therapeutics go up and down completely randomly.

Pair Corralation between NextCure and Achilles Therapeutics

Given the investment horizon of 90 days NextCure is expected to generate 1.08 times more return on investment than Achilles Therapeutics. However, NextCure is 1.08 times more volatile than Achilles Therapeutics PLC. It trades about 0.02 of its potential returns per unit of risk. Achilles Therapeutics PLC is currently generating about -0.01 per unit of risk. If you would invest  141.00  in NextCure on August 23, 2024 and sell it today you would lose (12.00) from holding NextCure or give up 8.51% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

NextCure  vs.  Achilles Therapeutics PLC

 Performance 
       Timeline  
NextCure 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Achilles Therapeutics PLC 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

NextCure and Achilles Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with NextCure and Achilles Therapeutics

The main advantage of trading using opposite NextCure and Achilles Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NextCure position performs unexpectedly, Achilles Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will offset losses from the drop in Achilles Therapeutics' long position.
The idea behind NextCure and Achilles Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Complementary Tools

Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
CEOs Directory
Screen CEOs from public companies around the world
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Volatility Analysis
Get historical volatility and risk analysis based on latest market data